Isatuximab 

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

An in-vitro study shows that the combination of Isatuximab with Pomalidomide results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1461640-62-9

Liquid

Colorless to light yellow

[Isatuximab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized CD38 Protein, Human can bind Isatuximab. The EC₅₀ for this effect is 6.163 ng/mL.

• [1]. Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912.  [Content Brief]

  [2]. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107.  [Content Brief]